Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 plus Gemcitabine in Stage IV Pancreatic Cancer
NCT01453153Phase 2Completed
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Sep 2011
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC), sponsored by Halozyme Therapeutics, Inc.. Started Sep 2011; status: completed.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01453153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453153.